Trial bolsters evidence in favor of closing hole in heart after stroke

March 12, 2018, American College of Cardiology

Among people with a type of hole in the heart, known as patent foramen ovale (PFO), those who received a medical device to close this opening after a stroke fared better after two years compared with those who received stroke-preventing medications alone. These findings from a study being presented at the American College of Cardiology's 67th Annual Scientific Session support the results of several similar trials in recent years and suggest patients with a high-risk PFO are likely to benefit most from the device.

PFO is a that occurs when a small hole between the top two chambers of the heart fails to fully close after birth. An estimated 1 in 4 people have a PFO, though many are undiagnosed. The condition does not typically cause symptoms but may increase the risk of . Among patients younger than 55 years of age who experience a stroke of unknown cause, a cryptogenic stroke, the prevalence of PFOs has been found to be around 46 percent, much higher than the rate of PFOs in the general population. The new findings add to a growing body of evidence that closing the PFO after this type of stroke can help prevent subsequent strokes and related problems, particularly in those with a high-risk PFO.

Researchers stopped enrollment for the trial early after determining, based on the results of several recent trials, that it would be unethical to continue assigning some patients to not receive the PFO closure device in light of mounting evidence of its clear benefits. Despite the smaller-than-expected number of participants, researchers said the new trial helps clarify which patients are likely to benefit most from the medical device based on the physical characteristics of their PFO.

"Considering the high prevalence of PFO in the and cryptogenic stroke patients, the key to appropriate use of this is determining how to select optimal candidates for the procedure," said Jae Kwan Song, MD, a cardiologist at Asan Medical Center in Seoul, South Korea and the study's lead author. "Our study showed that the potential benefit from closure can be determined on the basis of the size of the PFO and the movement of the heart wall around the PFO."

The trial enrolled 120 patients at two centers in South Korea. All patients had recently experienced a cryptogenic stroke and were found to have a high-risk PFO, meaning either the PFO was 2 millimeters across (about the size of a peppercorn) or larger, or the PFO was accompanied by an outgrowth of tissue protruding into one of the heart's chambers.

All patients received medications such as anticoagulants or antiplatelet drugs, which are recommended after a stroke to reduce the formation of blood clots and prevent subsequent strokes. The specific type of was determined by each patient's physician, although no direct oral anticoagulants (also known as novel oral anticoagulants) were used in the study. Half of the patients were randomly assigned to receive a PFO closure device, which interventional cardiologists implanted in the heart by threading the device through a vein in the groin, while the other half received medications alone.

Researchers followed patient outcomes for two years. The study's primary endpoint was a composite of stroke, major bleeding events and death from vascular causes (death related to the blockage or rupture of blood vessels). While no such events occurred in the 60 patients receiving PFO closure, among the 60 patients receiving medications alone, six had a stroke and one had a transient ischemic attack, or "mini-stroke." These results suggest that treating 10 PFOs with a closure would be expected to prevent, on average, about one stroke after two years.

"We believe that PFO closure should be done in selected patients with and PFO," Song said. "With our study and other recent trials, the criteria for selecting patients for the procedure are becoming clearer; in particular, the results suggest that closure is beneficial for those with high-risk PFO."

There are several available medications to prevent blood clots in people who have experienced a stroke, including antiplatelet drugs, direct oral anticoagulants and traditional anticoagulants such as warfarin. Because trials for PFO closure devices have been inconsistent in their selection of medications, Song said additional studies are needed to clarify the potential benefits of different medications when used post-stroke in with PFO.

Explore further: Compared with medical treatment, percutaneous closure procedures prevent recurrent stroke

Related Stories

Compared with medical treatment, percutaneous closure procedures prevent recurrent stroke

January 8, 2018
Two systematic evidence reviews and meta-analyses show that percutaneous closure procedures prevent recurrent stroke in patients with patent foramen ovale (PFO) compared with medical treatment alone. The first review was ...

RESPECT trial shows closing a small hole in heart may protect against recurrent stroke

September 13, 2017
A device used to close a small hole in the heart may benefit certain stroke patients by providing an extra layer of protection for those facing years of ongoing stroke risk, according to the results of a large clinical trial ...

When the cause of stroke is mystery, patent foramen ovale (PFO) could be the answer

October 31, 2016
A stroke occurs when a blood vessel to the brain is either blocked by a clot or bursts, preventing the brain from receiving the oxygen it needs to survive or directly damaging brain tissue.

Study shows PFO closure may be superior to medical therapy in preventing stroke

October 25, 2012
Results of a large-scale, randomized clinical trial called RESPECT revealed that patent foramen ovale (PFO) closure may be superior to medical therapy in preventing recurrent stroke, according to a presentation of findings ...

Results of trial to determine how to prevent future strokes encouraging

March 21, 2013
(Medical Xpress)—The results of a major, multicenter clinical trial to determine the best treatment for younger patients who have strokes that are potentially due to a hole in the upper chambers of the heart has provided ...

AAN: Closure not recommended for people with heart defect and stroke

July 27, 2016
An updated recommendation from the American Academy of Neurology (AAN) states that catheter-based closure should not be routinely recommended for people who have had a stroke and also have a heart defect called a patent foramen ...

Recommended for you

Exercise may be as effective as prescribed drugs to lower high blood pressure

December 18, 2018
Exercise may be as effective as prescribed drugs to lower high (140 mm Hg) blood pressure, suggests a pooled analysis of the available data, in what is thought to be the first study of its kind, and published online in the ...

Can stem cells help a diseased heart heal itself? Researchers achieve important milestone

December 14, 2018
A team of Rutgers scientists, including Leonard Lee and Shaohua Li, have taken an important step toward the goal of making diseased hearts heal themselves—a new model that would reduce the need for bypass surgery, heart ...

Your weight history may predict your heart failure risk

December 12, 2018
In a medical records analysis of information gathered on more than 6,000 people, Johns Hopkins Medicine researchers conclude that simply asking older adult patients about their weight history at ages 20 and 40 could provide ...

Higher risk of heart attack on Christmas Eve

December 12, 2018
The risk of heart attack peaks at around 10pm on Christmas Eve, particularly for older and sicker people, most likely due to heightened emotional stress, finds a Swedish study in this week's Christmas issue of The BMJ.

Age is the biggest risk for heart disease, but lifestyle and meds have impact

December 12, 2018
Of all the risk factors for heart disease, age is the strongest predictor of potential trouble.

New understanding of mysterious 'hereditary swelling'

December 12, 2018
For the first time ever, biomedical researchers from Aarhus University, Denmark, report cellular defects that lead to a rare disease, hereditary angioedema (HAE), in which patients experience recurrent episodes of swelling ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.